EpiDex® Swiss field trial 2004-2008.

Area of Science:

• Regenerative Medicine
• Dermatology
• Wound Healing

Background:

• Chronic leg ulcers affect 20% of patients, often resistant to conservative treatments.
• Current options include conventional skin grafts or managing intractable wounds.
• Cell-cultured skin substitutes present a promising, non-surgical alternative.

Purpose of the Study:

• To systematically evaluate the efficacy of EpiDex treatment in Swiss patients.
• Assessed outcomes in 68 patients with chronic wounds from 2004-2008.

Main Methods:

• Retrospective analysis of 68 patients with chronic wounds (leg ulcers and sores) unresponsive to standard care.
• Primary endpoint: complete wound closure within 9 months.
• Secondary endpoints: wound surface area reduction, pain decrease, patient satisfaction, and cost analysis.

Main Results:

• Complete wound healing achieved in 74% of patients (50/68).
• Significant wound pain reduction reported in 91% of patients (50/68 healed, 10/68 >50% reduction).
• Average treatment cost for venous ulcers was EUR 5,357, lower than in-patient skin graft costs.

Conclusions:

• EpiDex effectively heals up to 74% of recalcitrant chronic leg ulcers.
• It serves as an intermediate step, potentially avoiding costly in-patient skin grafts.
• EpiDex allows patient mobilization and avoids donor site morbidity, though large or necrotic wounds may limit its use.